RESUMEN
In humans, CD16 and CD56 are used to identify functionally distinct natural killer (NK) subsets. Due to ubiquitous CD56 expression, this marker cannot be used to distinguish between NK cell subsets in chimpanzees. Therefore, functional analysis of distinct NK subsets during hepatitis C virus (HCV) infection has never been performed in these animals. In the present study an alternative strategy was used to identify four distinct NK subsets on the basis of the expression of CD16 and CD94. The expression of activating and inhibiting surface receptors showed that these subsets resemble human NK subsets. CD107 expression was used to determine degranulation of the different subsets in naive and HCV-infected chimpanzees. In HCV-infected chimpanzees increased spontaneous cytotoxicity was observed in CD94(high/dim) CD16(pos) and CD94(low) CD16(pos) subsets. By contrast, increased natural cytotoxicity receptor (NCR)- mediated degranulation after NKp30 and NKp44 triggering was demonstrated in the CD94(dim) CD16(neg) subset. Our findings suggest that spontaneous and NCR-mediated cytotoxicity are effector functions of distinct NK subsets in HCV-infected chimpanzees.
Asunto(s)
Linaje de la Célula/inmunología , Citotoxicidad Inmunológica , Hepacivirus/inmunología , Hepatitis C/inmunología , Células Asesinas Naturales/inmunología , Animales , Enfermedades del Simio Antropoideo , Degranulación de la Célula/efectos de los fármacos , Citometría de Flujo , Regulación de la Expresión Génica , Hepatitis C/patología , Hepatitis C/virología , Inmunofenotipificación , Interleucina-2/farmacología , Interleucinas/farmacología , Células Asesinas Naturales/clasificación , Células Asesinas Naturales/citología , Células Asesinas Naturales/efectos de los fármacos , Activación de Linfocitos/efectos de los fármacos , Proteína 1 de la Membrana Asociada a los Lisosomas/genética , Proteína 1 de la Membrana Asociada a los Lisosomas/inmunología , Subfamília D de Receptores Similares a Lectina de las Células NK/genética , Subfamília D de Receptores Similares a Lectina de las Células NK/inmunología , Receptor 2 Gatillante de la Citotoxidad Natural/genética , Receptor 2 Gatillante de la Citotoxidad Natural/inmunología , Receptor 3 Gatillante de la Citotoxidad Natural/genética , Receptor 3 Gatillante de la Citotoxidad Natural/inmunología , Pan troglodytes , Receptores de IgG/genética , Receptores de IgG/inmunologíaRESUMEN
Macaques provide important animal models in biomedical research into infectious and chronic inflammatory disease. Therefore, a proper understanding of the similarities and differences in immune function between macaques and humans is needed for adequate interpretation of the data and translation to the human situation. Dendritic cells are important as key regulators of innate and adaptive immune responses. Using a new whole blood assay we investigated functional characteristics of blood plasmacytoid dendritic cells (pDC), myeloid dendritic cells (mDC) and monocytes in rhesus macaques by studying induction of activation markers and cytokine expression upon Toll-like receptor (TLR) stimulation. In a head-to-head comparison we observed that rhesus macaque venous blood contained relatively lower numbers of pDC than human venous blood, while mDC and monocytes were present at similar percentages. In contrast to humans, pDC in rhesus macaques expressed the interleukin (IL)-12p40 subunit in response to TLR-7/8 as well as TLR-9 stimulation. Expression of IL-12p40 was confirmed by using different monoclonal antibodies and by reverse transcription-polymerase chain reaction (RT-PCR). Both in humans and rhesus macaques, TLR-4 stimulation induced IL-12p40 expression in mDC and monocytes, but not in pDC. The data show that, in contrast to humans, pDC in macaques are able to express IL-12p40, which could have consequences for evaluation of human vaccine candidates and viral infection.
Asunto(s)
Células Dendríticas/inmunología , Subunidad p40 de la Interleucina-12/biosíntesis , Receptor Toll-Like 7/agonistas , Receptor Toll-Like 7/sangre , Receptor Toll-Like 8/agonistas , Receptor Toll-Like 8/sangre , Receptor Toll-Like 9/agonistas , Receptor Toll-Like 9/sangre , Animales , Células Dendríticas/metabolismo , Humanos , Subunidad p40 de la Interleucina-12/sangre , Subunidad p40 de la Interleucina-12/genética , Macaca mulattaRESUMEN
Tripartite motif 5α (TRIM5α) is a potent antiretroviral immune factor present in the cytoplasm of cells of most tissue types. The rhesus macaque TRIM5 gene has been shown to display polymorphism, with different variants being divided into three groups (TRIM5(TFP), TRIM5(Q), and TRIM5(CypA)), which may have divergent retroviral effects on infection. Along with rhesus macaques, cynomolgus macaques are also used in simian immunodeficiency virus (SIV) infection studies. As a consequence, TRIM5 genotyping of these animals will contribute to interpreting the outcome of such studies. The present communication covers Burmese, Chinese, and a large cohort of Indian-origin rhesus macaques, and describes the first large cohort study on TRIM5 polymorphism in outbred cynomolgus macaques. We demonstrate the presence of the TRIM5(TFP) group in cynomolgus macaques. In addition, we have re-evaluated historical samples of rhesus macaques challenged with SIV(mac251), a virus that has been reported to be partially suppressed by particular rhesus macaque TRIM5 variants.
Asunto(s)
Alelos , Proteínas Portadoras/genética , Macaca mulatta/genética , Polimorfismo Genético , Vacunas contra el SIDAS/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/genética , Virus de la Inmunodeficiencia de los Simios , Animales , Asia Sudoriental , Proteínas Portadoras/inmunología , Genotipo , Macaca fascicularis , Macaca mulatta/inmunología , Vacunas contra el SIDAS/genética , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & controlRESUMEN
The rapidly spreading HIV epidemic requires a vaccine that elicits potent mucosal immunity to halt or slow transmission. Induction of these responses will depend on the use of appropriate adjuvants and targeting of the mucosal immune system. Previously, immune stimulating complexes (ISCOM) have shown great potency as adjuvant in the induction of mucosal responses in mice and systemic responses in non-human primates. In this study, HIV formulated in PR8-Flu ISCOM adjuvant was applied to immunize rhesus macaques against HIV; targeting the mucosa either via intranasal (IN) application or via targeted lymph node immunization (TLNI). While, strong systemic, HIV specific, cytokine, lymphoproliferative, and antibody responses were induced via the TLNI route, the IN application generated only low responses. Furthermore, all four animals immunized via TLNI developed vaginal IgA antibodies against gp120. In conclusion, in contrast to what has been demonstrated in mice, the IN application of PR8-Flu ISCOM did not induce strong immune responses in rhesus macaques unlike those immunized by the TLNI route.
Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Adyuvantes Inmunológicos/administración & dosificación , Anticuerpos Anti-VIH/análisis , Infecciones por VIH/inmunología , VIH-1/inmunología , ISCOMs/administración & dosificación , Inmunización , Vacunas contra el SIDA/inmunología , Administración Intranasal , Animales , Especificidad de Anticuerpos , Femenino , Proteína p24 del Núcleo del VIH/administración & dosificación , Proteína p24 del Núcleo del VIH/inmunología , Proteína gp120 de Envoltorio del VIH/administración & dosificación , Proteína gp120 de Envoltorio del VIH/inmunología , Humanos , Esquemas de Inmunización , Inmunoglobulina A/análisis , Inyecciones Intralinfáticas , Macaca mulatta , Vacunas de Subunidad/administración & dosificación , Vagina/inmunologíaRESUMEN
Noroviruses, with Norwalk virus as the prototype strain, are the most common cause of viral gastroenteritis in people of all ages. Limited information on the immunology of Norovirus infections has been obtained by studies both in the natural setting and in experimentally infected volunteers. Interpretation of these studies is difficult due to the lack of information on the history of Norovirus exposure and the cross-reactivity of antibodies. An animal model for Norovirus infections would be important to study the immune response, e.g., for vaccine assessment. In the present study the susceptibility of common marmosets, cotton top tamarins, cynomolgus, and rhesus macaques to Norovirus infection was tested. Following oral inoculation, low level replication may have occurred in common marmosets and cotton top tamarins but not in cynomolgus macaques, based on short-term viral shedding; neither clinical symptoms nor antibody responses were observed in these species. In contrast, rhesus macaques were found susceptible to Norwalk virus infection as one animal shed virus for a longer period of time and developed Norwalk virus specific IgM and IgG responses. Further research on Norovirus susceptibility in rhesus macaques may yield an animal model to study the immune response and pathogenesis after Norovirus infection.
Asunto(s)
Infecciones por Caliciviridae/inmunología , Norovirus/aislamiento & purificación , Norovirus/patogenicidad , Sistema del Grupo Sanguíneo ABO , Animales , Anticuerpos Antivirales/sangre , Enfermedades del Simio Antropoideo/epidemiología , Antígenos de Grupos Sanguíneos , Infecciones por Caliciviridae/sangre , Infecciones por Caliciviridae/epidemiología , Infecciones por Caliciviridae/veterinaria , Callithrix/inmunología , Callithrix/virología , Modelos Animales de Enfermedad , Heces/virología , Macaca fascicularis/inmunología , Macaca fascicularis/virología , Macaca mulatta/inmunología , Macaca mulatta/virología , Enfermedades de los Monos/epidemiología , Norovirus/inmunología , Pan troglodytes/virología , ARN Viral/aislamiento & purificación , Saguinus/inmunología , Saguinus/virología , Esparcimiento de Virus/genéticaRESUMEN
Cell-surface CCR5 is a major coreceptor with CD4 glycoprotein, mediating cellular entry of CCR5 strains of HIV-1 or SIV. We targeted the SIV CCR5 coreceptor in a combined CCR5-SIV antigen immunization strategy. Rhesus macaques were immunized i.m. with the 70 kDa heat shock protein (HSP70) covalently linked to the CCR5 peptides, SIV gpl20 and p27. Intravenous challenge with SIV mac 8980 prevented SIV infection or decreased the viral load with the CCR5-SIV combined vaccine. CC chemokines and antibodies which block and downmodulateCCR5 were induced, as well as immune responses to the subunit SIV antigens. This novel vaccination strategy complements cognate immunity to SIV with innate immunity to the CCR5 coreceptor of SIV.
Asunto(s)
Receptores CCR5/inmunología , Vacunas contra el SIDAS/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Secuencia de Aminoácidos , Animales , Anticuerpos Antivirales/análisis , Anticuerpos Antivirales/biosíntesis , Antígenos de Superficie/inmunología , Antígenos Virales/inmunología , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Productos del Gen rex/genética , Productos del Gen rex/inmunología , Proteínas HSP70 de Choque Térmico/metabolismo , Esquemas de Inmunización , Inmunoglobulina A/análisis , Inmunoglobulina A/biosíntesis , Inmunoglobulina G/análisis , Inmunoglobulina G/biosíntesis , Cinética , Macaca mulatta , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/inmunología , Datos de Secuencia Molecular , Mycobacterium tuberculosis/inmunología , Linfocitos T/inmunología , Proteínas del Envoltorio Viral/genética , Proteínas del Envoltorio Viral/inmunologíaRESUMEN
Recent evidence suggests a much higher prevalence of human immunodeficiency virus type 1 (HIV-1) recombinants than previously anticipated. These recombinants arise from secondary HIV infections in individuals already infected with the virus. It remains unclear why some individuals acquire secondary HIV-1 infections and others do not. To address this question, a study was undertaken of a small cohort of chimpanzees with well-defined HIV-1 infection. After exposure to an infectious dose of heterologous primary isolate, 4 of 8 HIV-1 seropositive chimpanzees resisted secondary infection, whereas 2 naive controls became readily infected. Only animals who were immunologically boosted were protected. Protection from heterologous secondary exposure appeared to be related to the repertoire of the cytolytic CD8(+) T cell responses to HIV-1. Data suggested that immunologic boosting by HIV-1 antigens or exposure to subinfectious doses of virus may be important events in sustaining sufficient immunity to prevent secondary infections from occurring.
Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Síndrome de Inmunodeficiencia Adquirida/inmunología , Síndrome de Inmunodeficiencia Adquirida/prevención & control , Linfocitos T Citotóxicos/inmunología , Vacunas contra el SIDA/inmunología , Animales , Infecciones por VIH/inmunología , Pan troglodytesAsunto(s)
Vacunas contra el SIDA/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida/prevención & control , Modelos Animales de Enfermedad , Vacunas contra el SIDA/inmunología , Animales , Gatos , Diseño de Fármacos , VIH/inmunología , Humanos , Inmunidad Mucosa , Virus de la Inmunodeficiencia Felina/inmunología , Virus de la Anemia Infecciosa Equina/inmunología , Virus de la Inmunodeficiencia de los Simios/inmunologíaRESUMEN
A limited period of chemotherapy during primary immunodeficiency virus infection might provide a long-term clinical benefit even if treatment is initiated at a time point when virus is already detectable in plasma. To evaluate this strategy, we infected rhesus macaques with the pathogenic simian/human immunodeficiency virus RT-SHIV and treated them with the antiretroviral drug (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) for 8 weeks starting 7 or 14 days postinfection. PMPA treatment suppressed viral replication efficiently in all of the monkeys. After chemotherapy ended, virus replication rebounded and viral RNA in plasma reached levels comparable to that of the controls in four of the six monkeys. However, in the other two animals, virus loads peaked only moderately after withdrawal of the drug and then declined to low or even undetectable levels. These low levels of viremia remained stable for at least 31 weeks after cessation of therapy. At this time point, these two monkeys were challenged with SIV(8980) to evaluate whether the host responses which were able to keep RT-SHIV replication under control were also sufficient to protect against infection with a highly pathogenic heterologous virus. Both monkeys proved to be protected against the heterologous virus. In one of the two animals, low levels of SIV(8980) replication were detected. Thus, by chemotherapy during the acute phase of pathogenic virus replication, we could achieve not only persistent virus load suppression in two out of six monkeys but also protection from subsequent heterologous challenge. By this chemotherapeutic attenuation, the replication kinetics of attenuated viruses could be mimicked and a vaccination effect similar to that induced by live attenuated simian immunodeficiency virus vaccines was achieved.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/uso terapéutico , VIH-1 , Glicoproteínas de Membrana , Organofosfonatos , Compuestos Organofosforados/uso terapéutico , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida del Simio/tratamiento farmacológico , Virus de la Inmunodeficiencia de los Simios , Proteínas del Envoltorio Viral , Carga Viral , Adenina/efectos adversos , Adenina/uso terapéutico , Animales , Fármacos Anti-VIH/efectos adversos , Células Cultivadas , Proteína gp120 de Envoltorio del VIH/inmunología , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Transcriptasa Inversa del VIH/genética , VIH-1/enzimología , VIH-1/genética , Humanos , Subgrupos Linfocitarios , Macaca mulatta , Compuestos Organofosforados/efectos adversos , ARN Viral/sangre , Recombinación Genética , Inhibidores de la Transcriptasa Inversa/efectos adversos , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/fisiopatología , Síndrome de Inmunodeficiencia Adquirida del Simio/virología , Virus de la Inmunodeficiencia de los Simios/enzimología , Virus de la Inmunodeficiencia de los Simios/genética , Virus de la Inmunodeficiencia de los Simios/inmunología , TenofovirRESUMEN
Current strategies in human immunodeficiency virus type 1 (HIV-1) vaccine development are often based on the production of different vaccine antigens according to particular genetic clades of HIV-1 variants. To determine if virus virulence or genetic distance had a greater impact on HIV-1 vaccine efficacy, we designed a series of heterologous chimeric simian/human immunodeficiency virus (SHIV) challenge experiments in HIV-1 subunit-vaccinated rhesus macaques. Of a total of 22 animals, 10 nonimmunized animals served as controls; the remainder were vaccinated with the CCR5 binding envelope of HIV-1(W6.1D). In the first study, heterologous challenge included two nonpathogenic SHIV chimeras encoding the envelopes of the divergent clade B HIV-1(han2) and HIV-1(sf13) strains. In the second study, all immunized animals were rechallenged with SHIV(89. 6p), a virus closely related to the vaccine strain but highly virulent. Protection from either of the divergent SHIV(sf13) or SHIV(han2) challenges was demonstrated in the majority of the vaccinated animals. In contrast, upon challenge with the more related but virulent SHIV(89.6p), protection was achieved in only one of the previously protected vaccinees. A secondary but beneficial effect of immunization on virus load and CD4(+) T-cell counts was observed despite failure to protect from infection. In addition to revealing different levels of protective immunity, these results suggest the importance of developing vaccine strategies capable of protecting from particularly virulent variants of HIV-1.
Asunto(s)
Vacunas contra el SIDA/inmunología , Infecciones por VIH/prevención & control , VIH-1/inmunología , VIH-1/patogenicidad , Animales , Modelos Animales de Enfermedad , Proteína gp120 de Envoltorio del VIH/genética , Proteína gp120 de Envoltorio del VIH/inmunología , Proteína gp41 de Envoltorio del VIH/genética , Infecciones por VIH/inmunología , Infecciones por VIH/virología , Humanos , Macaca mulatta , Virus de la Inmunodeficiencia de los Simios/genética , Vacunas Atenuadas/inmunología , VirulenciaRESUMEN
Combination chemotherapy using potent anti-retroviral agents has led to significant advances in the clinical management of human immunodeficiency virus (HIV) disease. However, the emergence of multiple drug-resistant mutants, the high need for compliance to adhere to demanding drug-dosing schemes, and the remaining toxic side-effects of drugs make the perspective of life-long treatment unattractive and possibly unrealistic. Therefore, means must be sought to shorten the time span during which treatment is necessary. Such means could be to stimulate an efficient immune response during the period of low virus load and restored CD4 + cell levels, which might be capable of keeping the virus under long-lasting control after treatment is stopped. Here we tested this concept of combined chemotherapy/ therapeutic vaccination in a non-human primate model. Rhesus macaques chronically infected with the chimeric simian/human immunodeficiency virus (SHIV) containing the HIV type 1 (HIV-1) HXBc2 gene for reverse transcriptase (RT) in the genomic background of simian immunodeficiency virus (SIV)(mac239) (RT-SHIV) were treated with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA), a potent anti-HIV drug. When virus load had decreased significantly, we immunized with SIV genes env, gag/pol, rev, tat, and nef inserted in two different expression vector systems. Four weeks after the second immunization, drug treatment was stopped. Animals were monitored to determine if virus load stayed low or if it increased again to the original levels and if CD4+ T-cell levels remained stable. Humoral and cellular immune responses were also measured. This combined chemotherapy/ therapeutic vaccination regimen induced a significant reduction in the steady-state level of viremia in one out of two chronically infected rhesus macaques. Chemotherapeutic treatment alone did not achieve reduction of viremia in two chronically infected animals. The nature of the immune responses assumed to have been induced by vaccination in one out of the two monkeys remains to be elucidated.
Asunto(s)
Vacunas contra el SIDA , Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida del Simio/tratamiento farmacológico , Proteínas del Envoltorio Viral/genética , Adenina/análogos & derivados , Adenina/farmacología , Adenina/uso terapéutico , Animales , Fármacos Anti-VIH/farmacología , Recuento de Linfocito CD4 , Quimera , Terapia Combinada , Modelos Animales de Enfermedad , Genes Homeobox/genética , Vectores Genéticos , Infecciones por VIH/inmunología , Infecciones por VIH/prevención & control , VIH-1 , Humanos , Macaca mulatta , Organofosfonatos/farmacología , Organofosfonatos/uso terapéutico , Virus de los Bosques Semliki/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Tenofovir , Vacunación/veterinaria , Virus Vaccinia/inmunología , Proteínas del Envoltorio Viral/inmunología , Carga ViralRESUMEN
The seven-transmembrane G-protein-linked CCR5 molecule functions as a major coreceptor for HIV or simian immunodeficiency virus (SIV) infection. Antibodies to CCR5 were studied in rhesus macaques immunized with SIV grown in human CD4(+) T cells. These macaques were completely protected against i.v. challenge with live SIV. Sera from the protected macaques showed significantly greater inhibition of SIV replication (p < 0.001) and macrophage inflammatory protein-1beta-generated CCR5-dependent chemotaxis (p < 0.01) than sera from unprotected macaques, in the absence of significant neutralizing antibodies to SIV. These two functional assays demonstrate serum antibodies to the CCR5 receptors which were specifically inhibited by CCR5-transfected HEK-293 cells. We postulate that anti-CCR5 antibodies may be complementary to beta-chemokines in blocking CCR5 coreceptors to HIV or SIV binding and fusion of CD4(+) cells.
Asunto(s)
Receptores CCR5/inmunología , Receptores Virales/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Virus de la Inmunodeficiencia de los Simios/inmunología , Virus de la Inmunodeficiencia de los Simios/patogenicidad , Animales , Anticuerpos Monoclonales , Formación de Anticuerpos , Linfocitos T CD4-Positivos/inmunología , Línea Celular , Quimiotaxis de Leucocito/inmunología , Humanos , Inmunización , Inmunoglobulina G/sangre , Técnicas In Vitro , Macaca mulatta , Receptores CCR5/genética , Receptores del VIH/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Virus de la Inmunodeficiencia de los Simios/fisiología , Transfección , Replicación ViralRESUMEN
One of the obstacles to AIDS vaccine development is the variability of HIV-1 within individuals and within infected populations, enabling viral escape from highly specific vaccine induced immune responses. An understanding of the different immune mechanisms capable of inhibiting HIV infection may be of benefit in the eventual design of vaccines effective against HIV-1 variants. To study this we first compared the immune responses induced in Rhesus monkeys by using two different immunization strategies based on the same vaccine strain of HIV-1. We then utilized a chimeric simian/HIV that expressed the envelope of a dual tropic HIV-1 escape variant isolated from a later time point from the same patient from which the vaccine strain was isolated. Upon challenge, one vaccine group was completely protected from infection, whereas all of the other vaccinees and controls became infected. Protected macaques developed highest titers of heterologous neutralizing antibodies, and consistently elevated HIV-1-specific T helper responses. Furthermore, only protected animals had markedly increased concentrations of RANTES, macrophage inflammatory proteins 1alpha and 1beta produced by circulating CD8(+) T cells. These results suggest that vaccine strategies that induce multiple effector mechanisms in concert with beta-chemokines may be desired in the generation of protective immune responses by HIV-1 vaccines.
Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Quimiocinas CC/inmunología , VIH-1/inmunología , Animales , Citocinas/inmunología , VIH-1/fisiología , Inmunidad Celular , Macaca mulatta , Pruebas de Neutralización , Linfocitos T/inmunología , Linfocitos T/virologíaRESUMEN
Previous xenogeneic immunization experiments in rhesus macaques with simian immunodeficiency virus (SIV) grown in human CD4(+) T cells consistently elicited protection from challenge with live SIV. However, the mechanism of protection has not been established. We present evidence that xenogeneic immunization induced significant CD8 suppressor factor, RANTES (regulated upon activation, normal T cell expressed and secreted), macrophage inflammatory protein (MIP) 1alpha, and MIP-1beta (P < 0.001 - P < 0.02). The concentrations of these increased significantly in protected as compared with infected macaques (P < 0.001). Xenogeneic stimulation in vitro also up-regulated CD8 suppressor factors (SF; P < 0.001) and the beta chemokines which were neutralized by antibodies to the 3 beta chemokines. Recombinant human RANTES, MIP-1alpha and MIP-1beta which bind to simian CCR5, suppressed SIV replication in a dose-dependent manner, with RANTES being more effective than the other two chemokines. The results suggest that immunization with SIV grown in human CD4(+) T cells induces CD8-suppressor factor, RANTES, MIP-1alpha and MIP-1beta which may block CCR5 receptors and prevent the virus from binding and fusion to CD4(+) cells.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Quimiocinas CC/fisiología , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Factores Supresores Inmunológicos/fisiología , Animales , Humanos , Activación de Linfocitos , Macaca mulatta , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Virus de la Inmunodeficiencia de los Simios/crecimiento & desarrollo , Vacunación , Replicación Viral/efectos de los fármacosRESUMEN
OBJECTIVES: To investigate whether immunization with recombinant HIV-1 envelope protein derived from a clinical isolate could protect macaques from infection with an in vivo passaged chimeric simian-human immunodeficiency virus (SHIV). DESIGN AND METHODS: A total of 16 animals were studied from which three groups of four animals were immunized with vaccine formulations of the CC-chemokine receptor-5-binding recombinant gp120 of HIV-1W6.1D. Four weeks after the last immunization, all 16 animals were intravenously challenged with in vivo passaged SHIV derived from the same HIV-1 group B clinical isolate (W6.1D) as the vaccines. RESULTS: Vaccine protection from infection was demonstrated in 10 out of 12 macaques immunized with recombinant gp120. Complete protection from infection was achieved with all of the animals that received the SBAS2-W6.1D formulation, a potent inducer of both T-cell and humoral immune responses. Partial protection was achieved with SBAS1-W6.1D, a formulation based on immunomodulators known to induce T-cell responses in humans. In vaccinated animals that were infected, virus load was reduced and infection was delayed. CONCLUSIONS: In a relatively large number of primates, vaccine efficacy was demonstrated with a clinically relevant HIV-1 vaccine. These results reveal that it is possible to induce sterilizing immunity sufficient to protect from infection with SHIV which was passaged multiple times in vivo. Our findings have implications for current HIV-1 clinical vaccine trials and ongoing efforts to develop safe prophylactic AIDS vaccines.
Asunto(s)
Vacunas contra el SIDA , Proteína gp120 de Envoltorio del VIH/inmunología , Infecciones por VIH/prevención & control , VIH-1/inmunología , Virus de la Inmunodeficiencia de los Simios/inmunología , Vacunas Sintéticas , Vacunas contra el SIDA/inmunología , Animales , Afinidad de Anticuerpos , Quimera , Anticuerpos Anti-VIH/biosíntesis , Infecciones por VIH/inmunología , Inmunidad Celular , Macaca mulatta , Pruebas de Neutralización , Reacción en Cadena de la Polimerasa , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Virus de la Inmunodeficiencia de los Simios/genética , Vacunación , Vacunas Sintéticas/inmunologíaRESUMEN
The aim of the study was to select, from a panel of candidate European human immunodeficiency virus type 1 (HIV-1) clade B primary virus isolates, one isolate based on replication properties in chimpanzee peripheral blood mononuclear cells (PBMC). Secondly, to evaluate the in vivo kinetics of primary infection of the selected isolate at two different doses in two mature, outbred chimpanzees (Pan troglodytes). Four different low passage, human PBMC-cultured 'primary' HIV-1 isolates with European clade B consensus sequence were compared for their ability to replicate in vitro in chimpanzee versus human PBMC. The isolate which yielded the highest titre and most vigorous cytopathic effect in chimpanzee PBMC was evaluated for coreceptor usage and chosen for evaluation in vivo. Only the HIV-1Han2 isolate replicated in chimpanzee PBMC in vitro at detectable levels. This isolate was demonstrated to utilize CCR4, CCR5 and CXCR4 coreceptors and could be inhibited by beta-chemokines. Infection of chimpanzees was demonstrated by viral RNA and DNA PCR analysis, both in plasma as well as in PBMC and lymph node cells as early as 3 weeks after inoculation. Antibodies developed within 6 weeks and continued to increase to a maximum titre of approximately 12800, thereafter remaining in this range over the follow-up period of 2 years. Compared to cell line-adapted HIV-1 isolates there were slight but no dramatic differences in the kinetics of infection of chimpanzees with this particular primary isolate.
Asunto(s)
Infecciones por VIH/virología , VIH-1/fisiología , Animales , Línea Celular , Quimiocinas CC/metabolismo , ADN Viral , Modelos Animales de Enfermedad , Europa (Continente) , Citometría de Flujo , Anticuerpos Anti-VIH/sangre , Infecciones por VIH/sangre , Infecciones por VIH/inmunología , VIH-1/genética , VIH-1/inmunología , VIH-1/aislamiento & purificación , Humanos , Pan troglodytes , ARN Viral , Receptores del VIH/metabolismoRESUMEN
Rhesus monkeys were successfully vaccinated using a strategy of priming with a candidate envelope subunit vaccine and boosting with synthetic peptides. Priming was carried out with recombinant HIV-1 SF2 envelope glycoprotein incorporated into ISCOMs, following the attachment of a lipid tail. Peptides, covalently linked to ISCOMs, representing linear sequences with the V2 and V3 regions, were used to boost functional antibodies-to neutralizing epitopes in both of these regions. Injections with these peptide formulations substantially increased the titre of serum neutralizing antibodies from low or undetectable levels. In addition to completely neutralizing the homologous HIV-1 SF2 strain, these sera also neutralized the escape variant, HIV-1 SF13. However, no antibodies were boosted which could compete with human, neutralizing monoclonal antibodies recognising conformational epitopes. The peptides also boosted antibodies to a peptide whose sequence lies close to the V2 region neutralizing epitope but does not overlap with it. Importantly, the level of antibodies to an unrelated epitope associated with enhancement of HIV-1 SF13 continued to fall after the peptide boost. Successful protection against challenge with chimeric simian immunodeficiency virus expressing HIV-1 SF13 envelope glycoproteins (SHIV SF13) may be due to an increase in the ratio of neutralizing to enhancing antibodies by selectively boosting with peptides to critical neutralizing epitopes.
Asunto(s)
Vacunas contra el SIDA/inmunología , Epítopos , Anticuerpos Anti-VIH/sangre , Proteína gp120 de Envoltorio del VIH/inmunología , Vacunas Sintéticas/inmunología , Secuencia de Aminoácidos , Animales , Humanos , Inmunización Secundaria , Macaca mulatta , Datos de Secuencia MolecularRESUMEN
The use of HIV-1 env/SIVmac chimeric viruses expressing divergent HIV-1 envelopes of clinical isolates, facilitates homologous and heterologous evaluation of various recombinant HIV-1 envelope vaccine candidates in lower primates. In this study we compare the in vitro and in vivo infectivity, via intravenous (IV) and intravaginal (IVAG) routes of infection, of stocks of chimeric viruses expressing env from four different clade B HIV-1 isolates. The TCID50/ml was 7.1 x 10(4), 1.0 x 10(4), 6.3 x 10(4), and 1.2 x 10(3) for SHIVsf13, SHIVHan2, SHIVNM-3rn, and SHIVW6.1D, respectively, with a MID50/ml upon IV inoculation of 3.2 x 10(3), 3.2 x 10(4), 3.2 x 10(4), and 3.2 x 10(3), respectively. The same SHIVsf13 stock was infectious after IVAG administration, requiring a 300-fold higher virus dose. Plasma antigenemia and cell-associated viremia were generally highest at weeks 2 or 4 after infection and decreased to subdetectable levels after 8-12 weeks. All infected animals tested developed anti-HIV-1 gp120 antibodies. Inoculated virus dose showed no (linear) quantitative correlation with cellular virus load, duration of viremia, plasma antigenemia, and anti-gp120 antibody titers. No significant changes in peripheral blood CD4 cell levels were observed and none of the animals has shown evidence of disease progression to date (i.e., 13 months postinfection). Four in vivo passages of cell-associated SHIVW6.1D did not result in increased virulence. Vaccine development studies in macaques monkeys have become feasible with the use of various clade B HIV-1 env SHIV chimeras.
Asunto(s)
Quimera , Productos del Gen env/biosíntesis , Genes env , VIH-1/patogenicidad , Leucocitos Mononucleares/virología , Virus de la Inmunodeficiencia de los Simios/patogenicidad , Animales , ADN Viral/sangre , Femenino , VIH-1/genética , Humanos , Macaca mulatta , Provirus/genética , Provirus/patogenicidad , Proteínas Recombinantes de Fusión/biosíntesis , Virus de la Inmunodeficiencia de los Simios/genética , Vagina , Viremia , VirulenciaRESUMEN
Immune responses mediated by CD8+ lymphocytes have been correlated with protection from HIV infection and disease progression in humans and nonhuman primates. The CD8+ cell population is heterogeneous in terms of biological function and phenotype. We have undertaken a review of the current state of knowledge of subtypes of CD8+ cells and their role in immune responses directed to HIV and related primate lentiviruses. Differences in the pathogenesis of lentivirus infections in various primate hosts were examined and the possible roles of the various subpopulations of CD8+ lymphocytes in the resistance and/or susceptibility to lentivirus-related disease were compared.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Infecciones por VIH/inmunología , Inmunidad Celular/fisiología , Infecciones por Lentivirus/inmunología , Lentivirus de los Primates , Primates , Animales , Susceptibilidad a Enfermedades/inmunología , Susceptibilidad a Enfermedades/veterinaria , Susceptibilidad a Enfermedades/virología , Infecciones por VIH/veterinaria , Inmunidad Innata , Infecciones por Lentivirus/veterinaria , Subgrupos Linfocitarios/inmunología , Primates/inmunología , Primates/virologíaRESUMEN
OBJECTIVES: To determine whether prior infection with simian immunodeficiency virus (SIV)BK28 protects macaques from subsequent exposure to an HIV-1 envelope chimeric SIV (SHIV). Also, to determine the consequences of viral challenge on CD4 numbers and virus load on the current SIV infection. DESIGN AND METHODS: A total of 12 mature outbred Macacca mulatta were studied. Four naive controls and four previously infected with attenuated SIVBK28 were challenged with SHIV; four naive controls were not infected with SHIV. Sampling occurred twice monthly, and monthly thereafter. Changes in virus load, CD4 and CD8 populations were monitored. Highly sensitive and specific discriminative polymerase chain reaction (PCR) assays were used to distinguish between virus populations. RESULTS: SHIV readily infected challenged control animals, which developed a peak in virus load and a decline in CD4+ cell numbers. In controls, viral load declined and CD4 cell numbers rose to near normal levels after seroconversion. In contrast, in SIV-infected animals there was only a minor increase in viral load in only two out of four animals, 100-1000-fold lower than in naive animals. Interestingly, a decline in CD4 cells occurred in all four SIV-infected animals after SHIV challenge, which appeared more pronounced than in animals infected by SHIV alone. One SIV-infected animal which had low CD4 cell numbers at the time of SHIV challenge, developed a further decline in CD4 cells with a rising viral load. Discriminative PCR did not reveal SHIV in the challenged SIV animals. Interestingly the increase in viral load was due to SIV and not SHIV. CONCLUSIONS: Broad protection of animals previously infected with live attenuated SIV was demonstrated with protection from subsequent infection with HIV-1 envelope-bearing chimeric SIV. Subsequent exposure in cases with low CD4 cell numbers reveal the possibility of activation of the vaccine strain with the possible risk of inducing disease progression.